Document is current
Any future updates will be listed below
-
Authors
Nwabufo, Chukwunonso K.
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (FBD-181381)
- License Information
-
More Information
Article History
Received: 4 March 2025
Accepted: 30 April 2025
First Online: 22 May 2025
Declarations
:
: All the four participating TIBDN hospitals approved the research (REB# 2024–0233-1025, MED-02–011, SUN-5024, and 084–0209-Lab-001), and all patients provided informed consent.
: CKN was a former employee of Gilead Sciences and was involved in the development of remdesivir. CKN is employed by OneDrug Inc. The author does not have any conflicting interests associated with this research.
